Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Bullish +72

Insider Selling: Edwards Lifesciences (NYSE:EW) VP Sells 48,900 Shares ...

Insider transaction AI-generated analysis

πŸ“‰ VP Donald Bobo, Jr. sold 48,900 shares for $5.04 million under a pre-arranged Rule 10b5-1 trading plan on November 9th.

πŸ’° The company reported Q3 EPS of $0.80, beating the consensus estimate of $0.74 by $0.06.

πŸ“ˆ Revenue reached $1.72 billion, surpassing the $1.68 billion consensus and growing 10.5% year-over-year.

🏦 Institutional ownership stands at 79.46%, with Intech Investment Management increasing its stake by 123.9% in Q3.

🎯 Analysts maintain a 'Moderate Buy' consensus with an average price target of $108.88, up from recent lows.

πŸ“Š The stock trades at a P/E ratio of 59.16 and has a market capitalization of $60.29 billion.

Bullish Signals
  • Edwards Lifesciences beat Q3 earnings estimates with $0.80 EPS versus the consensus of $0.74.
  • Revenue grew 10.5% year-over-year to $1.72 billion, exceeding analyst expectations of $1.68 billion.
  • Goldman Sachs raised its price target to $102.00 and reaffirmed a 'buy' rating on the stock.
  • Intech Investment Management increased its stake by 123.9% in Q3, now holding shares valued at $16.6 million.
  • Truist Financial set a price objective of $113.00 with a 'buy' rating following the earnings beat.
  • Piper Sandler raised its price target to $115.00 and maintained an 'overweight' rating on the company.
Risk Factors
  • VP Donald Bobo, Jr. reduced his personal shareholding by 68.2% following a $5.04 million sale.
  • The stock trades at a high P/E ratio of 59.16, which may limit upside potential if growth slows.
Full Analysis
Edwards Lifesciences Corporation (NYSE:EW) saw Vice President Donald Bobo, Jr. sell 48,900 shares on November 9th under a pre-arranged Rule 10b5-1 trading plan. The transaction averaged $103.05 per share, totaling approximately $5.04 million, reducing his personal holding to roughly 22,798 shares. This insider sale represents a significant decrease in his position but was executed via a standard compliance plan. The company reported strong quarterly financial results on November 4th, beating analyst expectations for both earnings per share and revenue. Edwards Lifesciences posted $0.80 EPS compared to the consensus of $0.74, while revenue reached $1.72 billion against an estimate of $1.68 billion. Year-over-year revenue growth stood at 10.5%, driven by its structural heart disease therapies and critical care technologies. Market sentiment remains robust with a consensus price target of $108.88, supported by recent upgrades from major analysts including Goldman Sachs, Jefferies, and Truist Financial. Institutional ownership is high at 79.46%, with several funds like Intech Investment Management increasing their stakes in the third quarter. The stock trades at a P/E ratio of 59.16 with a market capitalization of $60.29 billion.